[1]王 楠.替罗非班对急性缺血性脑卒中患者新发脑微出血的影响[J].医学信息,2021,34(14):114-116.[doi:10.3969/j.issn.1006-1959.2021.14.030]
　WANG Nan.The Effect of Tirofiban on New Cerebral Microhemorrhage in Patients with Acute Ischemic Stroke[J].Medical Information,2021,34(14):114-116.[doi:10.3969/j.issn.1006-1959.2021.14.030]
点击复制

替罗非班对急性缺血性脑卒中患者新发脑微出血的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年14期
页码:
114-116
栏目:
论著
出版日期:
2021-07-15

文章信息/Info

Title:
The Effect of Tirofiban on New Cerebral Microhemorrhage in Patients with Acute Ischemic Stroke
文章编号:
1006-1959（2021）14-0114-03
作者:
王 楠
（佳木斯市中心医院神经内科，黑龙江 佳木斯 154002）
Author(s):
WANG Nan
(Department of Neurology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
替罗非班; 急性缺血性脑卒中; 新发脑微出血
Keywords:
Tirofiban; Acute ischemic stroke; New cerebral microhemorrhage
分类号:
R743.3
DOI:
10.3969/j.issn.1006-1959.2021.14.030
文献标志码:
A
摘要:
目的 分析替罗非班对急性缺血性脑卒中患者新发脑微出血的影响。方法 选取2019年11月~2020年11月在我院诊治的94例急性缺血性脑卒中患者为研究对象，采用随机数字表法分为对照组和观察组，各47例。对照组采用常规治疗，观察组在对照组基础上采用替罗非班治疗，比较两组血管开通率、血管再闭塞率、新发脑微出血发生率、NIHSS评分、运动功能评分、不同时间段血小板聚集率、凝血功能指标以及不良反应发生率。结果 观察组血管开通率（87.23%）高于对照组（76.59%），血管再闭塞率（6.38%）低于对照组（17.02%），差异有统计学意义（P＜0.05）；两组新发脑微出血发生率比较，差异无统计学意义（P＞0.05）；观察组NIHSS评分低于对照组，运动功能评分高于对照组，差异有统计学意义（P＜0.05）；观察组治疗1 h后、停药1 h血小板聚集率均低于对照组，差异有统计学意义（P＜0.05）；观察组PT、APTT均高于对照组，FIB、DDI均低于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 替罗非班应用于急性缺血性脑卒中不会增加新发脑微出血发生率，可提高血管开通率，降低血管再闭塞率，改善神经功能缺损和运动功能评分，降低血小板聚集率，安全性良好。
Abstract:
Objective To analyze the effect of tirofiban on new cerebral microhemorrhage in patients with acute ischemic stroke.Methods 94 patients with acute ischemic stroke who were diagnosed and treated in our hospital from November 2019 to November 2020 were selected as the research objects. They were divided into control group and observation group by random number table method, with 47 cases in each group.The control group was treated with conventional treatment, and the observation group was treated with tirofiban on the basis of the control group. The two groups were compared with the vascular open rate, vascular reocclusion rate, incidence of new cerebral microhemorrhage, NIHSS score, motor function score, and different time periods. Platelet aggregation rate, coagulation function index and incidence of adverse reactions.Results The vascular open rate (87.23%) of the observation group was higher than that of the control group (76.59%), and the reocclusion rate of blood vessels (6.38%) was lower than that of the control group (17.02%),the difference was statistically significant (P<0.05);There was no significant difference in the incidence of new cerebral microhemorrhage between the two groups (P>0.05);The NIHSS score of the observation group was lower than that of the control group, and the motor function score was higher than that of the control group, the difference was statistically significant (P<0.05);The platelet aggregation rate of the observation group was lower than that of the control group after 1 h of treatment and 1 hof drug withdrawal,the difference was statistically significant (P＜0.05);The PT and APTT of the observation group were higher than those of the control group, and the FIB and DDI were lower than those of the control group, the difference was statistically significant (P<0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Tirofiban used in acute ischemic stroke does not increase the incidence of new cerebral microhemorrhage.It can increase the rate of vascular opening, reduce the rate of reocclusion of blood vessels, improve neurological deficits and motor function scores, reduce the rate of platelet aggregation, and have good safety.

参考文献/References:

[1]周苗,庞国防,姜蔼玲,等.血脂代谢与缺血性脑卒中患者脑出血转化的相关性研究[J].中国现代医生,2016,54(28):1-4,8. [2]赵学栋,石秋艳,张春阳,等.磁共振成像指导觉醒型卒中患者静脉溶栓的安全性及预后分析[J].中国煤炭工业医学杂志,2016,19(5):679-683． [3]杜卫,李靖宇,尹茹,等.缺血性脑卒中合并脑微出血中国缺血性卒中亚型分型危险因素分析[J].神经损伤与功能重建,2019,14(12):638-640. [4]滕振杰,董艳红,李玲,等.脑微出血与急性缺血性卒中的临床关系分析[J].中国神经免疫学和神经病学杂志,2016,23(5):312-316,321. [5]Gueniat J,Breniere C,Graber M,et al.Increasing Burden of Stroke: The Dijon Stroke Registry (1987-2012)[J].Neuroepidemiology,2018,50(1-2):47-56. [6]王金波.氯吡格雷联合阿司匹林治疗进展性动脉粥样硬化缺血性脑卒中的临床疗效[J].湖南中医药大学学报,2016(A02):927-927. [7]徐金静,靳玉娟,吕静静.急性缺血性脑卒中伴脑微出血与2型糖尿病及糖化血红蛋白的相关性分析[J].解放军医药杂志,2020,32(11):80-83. [8]李增祥,张琼琼,李朝.糖化血红蛋白及血脂水平与老年急性缺血性脑卒中伴脑微出血的相关性[J].临床心身疾病杂志,2018,24(3):8-11. [9]LI S,Xu F,He J,et al.Re-look at socioeconomic inequalities in stroke prevalence among urban Chinese:is the inflexion approaching[J].BMC Public Health,2018,18(1):367. [10]曹娟,刘传玉.烟台市城乡脑卒中危险因素的暴露水平比较分析[J].卒中与神经疾病,2019,26(2):59-62. [11]张宇,汤颖,王红.等.大动脉粥样硬化型急性缺血性脑卒中患者入院后首个24 h内血压变异与出院结局[J].中华疾病控制杂志,2018,22(8):776-780. [12]刘国玲.脑微出血与不同亚型缺血性脑卒中的关系及预后分析[J].国际神经病学神经外科学杂志,2017,44(6):582-586. [13]王凯,荣良群,魏秀娥,等.脑微出血与急性缺血性卒中患者早期神经功能恶化的相关性[J].国际脑血管病杂志,2018(6):428-433. [14]黄美媚,钟剑萍,黎宏庄,等.血脂、血清β-AP和尿酸水平与急性脑梗死患者脑内微出血及预后的关系[J].山东医药,2017,57(11):66-69. [15]舒俊龙,黄一宁,李凡,等.脑血管病患者脑微出血的危险因素分析[J].中国全科医学,2019,22(23):2793-2797.

相似文献/References:

[1]王跃慧.急性缺血性脑卒中的药物治疗[J].医学信息,2022,35(11):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
　WANG Yue-hui.Drug Treatment of Acute Ischemic Stroke[J].Medical Information,2022,35(14):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
[2]雷 锐,李 志.冠状动脉介入及替罗非班治疗老年急性心肌梗死并 心源性休克的疗效分析[J].医学信息,2018,31(14):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
　LEI Rui,LI Zhi.Effect of Coronary Intervention and Tirofiban on Elderly Patients with Acute Myocardial Infarction and Cardiogenic Shock[J].Medical Information,2018,31(14):150.[doi:10.3969/j.issn.1006-1959.2018.14.046]
[3]王珊珊.国内丁苯肽治疗急性缺血性脑卒中机制的应用研究[J].医学信息,2019,32(09):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
　WANG Shan-shan.Study on the Application of Domestic Butyl Phenyl Peptide in the Treatment of Acute Ischemic Stroke[J].Medical Information,2019,32(14):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
[4]郑钰蓉,殷 梅,罗 悯.急性缺血性脑卒中伴发脑心综合征的临床研究[J].医学信息,2022,35(17):156.[doi:10.3969/j.issn.1006-1959.2022.17.043]
　ZHENG Yu-rong,YIN Mei,LUO Min.Clinical Study of Acute Ischemic Stroke with Cerebrocardiac Syndrome[J].Medical Information,2022,35(14):156.[doi:10.3969/j.issn.1006-1959.2022.17.043]
[5]宋贵军.急性缺血性脑卒中静脉溶栓治疗[J].医学信息,2020,33(17):47.[doi:10.3969/j.issn.1006-1959.2020.17.014]
　SONG Gui-jun.Intravenous Thrombolytic Therapy for Acute Ischemic Stroke[J].Medical Information,2020,33(14):47.[doi:10.3969/j.issn.1006-1959.2020.17.014]
[6]雷 锐,李 志.PCI术前应用替罗非班对急性心肌梗死患者PCI治疗效果的影响[J].医学信息,2022,35(21):119.[doi:10.3969/j.issn.1006-1959.2022.21.030]
　LEI Rui,LI Zhi.Effect of Tirofiban on PCI in Patients with Acute Myocardial Infarction Before PCI[J].Medical Information,2022,35(14):119.[doi:10.3969/j.issn.1006-1959.2022.21.030]
[7]褚春沐.血浆纤维蛋白原和D-二聚体在急性缺血性脑卒中治疗中的应用价值[J].医学信息,2022,35(21):101.[doi:10.3969/j.issn.1006-1959.2022.21.024]
　CHU Chun-mu.The Application Value of Plasma Fibrinogen and D-dimer in the Treatment of Acute Ischemic Stroke[J].Medical Information,2022,35(14):101.[doi:10.3969/j.issn.1006-1959.2022.21.024]
[8]罗贤云.阿托伐他汀联合双抗治疗对急性缺血性脑卒中患者血脂、神经功能及预后的影响[J].医学信息,2022,35(23):133.[doi:10.3969/j.issn.1006-1959.2022.23.027]
　LUO Xian-yun.Effect of Atorvastatin Combined with Double Antibody Therapy on Blood Lipid, Neurological Function and Prognosis in Patients with Acute Ischemic Stroke[J].Medical Information,2022,35(14):133.[doi:10.3969/j.issn.1006-1959.2022.23.027]
[9]王 楠.肠内营养联合双歧杆菌三联活菌对神经介入治疗后急性缺血性脑卒中患者二胺氧化酶及营养指标的影响[J].医学信息,2021,34(15):169.[doi:10.3969/j.issn.1006-1959.2021.15.047]
　WANG Nan.The Effect of Enteral Nutrition Combined with Live Bifidobacterium Triple Bacteria on Diamine Oxidase and Nutritional Indicators in Patients with Acute Ischemic Stroke After Neurointerventional Therapy[J].Medical Information,2021,34(14):169.[doi:10.3969/j.issn.1006-1959.2021.15.047]
[10]钮 静,权文娟,赵春洪,等.优化静脉溶栓流程在改善急性缺血性脑卒中患者即时疗效的应用[J].医学信息,2021,34(20):139.[doi:10.3969/j.issn.1006-1959.2021.20.036]
　NIU Jing,QUAN Wen-juan,ZHAO Chun-hong,et al.Application of Optimizing Intravenous Thrombolysis Process in Improving Immediate Efficacy ofPatients with Acute Ischemic Stroke[J].Medical Information,2021,34(14):139.[doi:10.3969/j.issn.1006-1959.2021.20.036]

更新日期/Last Update: 1900-01-01